InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.570
+0.010 (0.64%)
Oct 30, 2024, 4:00 PM EDT - Market closed
InflaRx Revenue
InflaRx had revenue of 6.36K EUR in the quarter ending June 30, 2024. This brings the company's revenue in the last twelve months to 105.48K. In the year 2023, InflaRx had annual revenue of 63.09K.
Revenue (ttm)
105.48K EUR
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
1,696 EUR
Employees
62
Market Cap
92.45M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionIFRX News
- 5 weeks ago - InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress - GlobeNewsWire
- 2 months ago - InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases - GlobeNewsWire
- 2 months ago - InflaRx Announces Participation in September Investor Events - GlobeNewsWire
- 3 months ago - InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - InflaRx to Report Second Quarter 2024 Results on August 8, 2024 - GlobeNewsWire
- 4 months ago - InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS) - GlobeNewsWire
- 5 months ago - InflaRx Hosts R&D Event Highlighting the Promise of INF904 - GlobeNewsWire
- 5 months ago - InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators - GlobeNewsWire